Kidney Cancer Drugs Market Report

China Kidney Cancer Drugs Industry Market Research Report 2023-2029

  • POSTDATE：Oct 12, 2023
  • PAGES：212
  • REPORT CODE：GMM1847359
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.

    Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

    This report elaborates on the current development of the Kidney Cancer Drugs industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Exelixis

    • Genentech

    • Taiwan Liposome

    • Wilex

    • Abbott Laboratories

    • GlaxoSmithKline

    • Argos Therapeutics

    • Roche

    • Seattle Genetics

    • Onyx Therapeutics

    • AVEO Pharmaceuticals

    • Bristol-Myers Squibb

    • Prometheus Laboratories

    • Bionomics

    • ArQule

    • Novartis

    • Pfizer

    • Amgen

    • Tracon Pharmaceuticals

    • Bayer

    • Ono Pharmaceutical

    • immatics biotechnologies

    • Active Biotech

    By Type:

    • mTOR Inhibitors

    • Cytokine Immunotherapy (IL-2)

    • Monoclonal Antibodies

    • Angiogenesis Inhibitors

    By Application:

    • Transitional cell carcinoma (TCC)

    • Renal cell carcinoma (RCC)

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Kidney Cancer Drugs Market Overview 2018-2029

    • 1.1 China Kidney Cancer Drugs Industry Development Overview

    • 1.2 China Kidney Cancer Drugs Industry Development History

    • 1.3 China Kidney Cancer Drugs Industry Market Size (2018-2029)

    • 1.4 China Kidney Cancer Drugs Market Analysis by Type from Production Side

      • 1.4.1 China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of mTOR Inhibitors (2018-2029)

      • 1.4.2 China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of Cytokine Immunotherapy (IL-2) (2018-2029)

      • 1.4.3 China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of Monoclonal Antibodies (2018-2029)

      • 1.4.4 China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of Angiogenesis Inhibitors (2018-2029)

    • 1.5 China Kidney Cancer Drugs Market Analysis by Application from Consumption End

      • 1.5.1 China Kidney Cancer Drugs Sales Volume, Sales Value and Growth Rate of Transitional cell carcinoma (TCC) (2018-2029)

      • 1.5.2 China Kidney Cancer Drugs Sales Volume, Sales Value and Growth Rate of Renal cell carcinoma (RCC) (2018-2029)

    • 1.6 China Kidney Cancer Drugs Market Analysis by Region

      • 1.6.1 North China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    Chapter 2 China Kidney Cancer Drugs Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Kidney Cancer Drugs Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Kidney Cancer Drugs Market Status and Competition Analysis in 2023

      • 2.2.3 China Kidney Cancer Drugs Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Kidney Cancer Drugs Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Kidney Cancer Drugs Industry Development

    Chapter 3 Kidney Cancer DrugsIndustry Chain Analysis

    • 3.1 Kidney Cancer Drugs Industry Chain

    • 3.2 Kidney Cancer Drugs Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Kidney Cancer Drugs Market

    • 3.3 Kidney Cancer Drugs Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Kidney Cancer Drugs Market

    Chapter 4 China Kidney Cancer Drugs Market, by Type

    • 4.1 China Kidney Cancer Drugs Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Kidney Cancer Drugs Total Production Volume and Growth Rate from Production Side

    • 4.5 China Kidney Cancer Drugs Production Volume and Growth Rate, by Type

      • 4.5.1 China Kidney Cancer Drugs Production Volume and Growth Rate of mTOR Inhibitors

      • 4.5.2 China Kidney Cancer Drugs Production Volume and Growth Rate of Cytokine Immunotherapy (IL-2)

      • 4.5.3 China Kidney Cancer Drugs Production Volume and Growth Rate of Monoclonal Antibodies

      • 4.5.4 China Kidney Cancer Drugs Production Volume and Growth Rate of Angiogenesis Inhibitors

    Chapter 5 China Kidney Cancer Drugs Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Kidney Cancer Drugs Total Market Size and Growth Rate from Consumption End

    • 5.5 China Kidney Cancer Drugs Market Size and Growth Rate, by Application

      • 5.5.1 China Kidney Cancer Drugs Market Size and Growth Rate of Transitional cell carcinoma (TCC)

      • 5.5.2 China Kidney Cancer Drugs Market Size and Growth Rate of Renal cell carcinoma (RCC)

    Chapter 6 China Kidney Cancer Drugs Market, by Region

    • 6.1 China Kidney Cancer Drugs Production Volume and Production Value, by Region

    • 6.2 China Kidney Cancer Drugs Sales Volume and Sales Value, by Region

    Chapter 7 North China Kidney Cancer Drugs Market Analysis

    • 7.1 North China Kidney Cancer Drugs Market, by Type

    • 7.2 North China Kidney Cancer Drugs Market, by Application

    Chapter 8 Central China Kidney Cancer Drugs Market Analysis

    • 8.1 Central China Kidney Cancer Drugs Market, by Type

    • 8.2 Central China Kidney Cancer Drugs Market, by Application

    Chapter 9 South China Kidney Cancer Drugs Market Analysis

    • 9.1 South China Kidney Cancer Drugs Market, by Type

    • 9.2 South China Kidney Cancer Drugs Market, by Application

    Chapter 10 East China Kidney Cancer Drugs Market Analysis

    • 10.1 East China Kidney Cancer Drugs Market, by Type

    • 10.2 East China Kidney Cancer Drugs Market, by Application

    Chapter 11 Northeast China Kidney Cancer Drugs Market Analysis

    • 11.1 Northeast China Kidney Cancer Drugs Market, by Type

    • 11.2 Northeast China Kidney Cancer Drugs Market, by Application

    Chapter 12 Southwest China Kidney Cancer Drugs Market Analysis

    • 12.1 Southwest China Kidney Cancer Drugs Market, by Type

    • 12.2 Southwest China Kidney Cancer Drugs Market, by Application

    Chapter 13 Northwest China Kidney Cancer Drugs Market Analysis

    • 13.1 Northwest China Kidney Cancer Drugs Market, by Type

    • 13.2 Northwest China Kidney Cancer Drugs Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Exelixis

        • 14.1.1 Exelixis Company Profile

        • 14.1.2 Exelixis Kidney Cancer Drugs Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Genentech

        • 14.2.1 Genentech Company Profile

        • 14.2.2 Genentech Kidney Cancer Drugs Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Taiwan Liposome

        • 14.3.1 Taiwan Liposome Company Profile

        • 14.3.2 Taiwan Liposome Kidney Cancer Drugs Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Wilex

        • 14.4.1 Wilex Company Profile

        • 14.4.2 Wilex Kidney Cancer Drugs Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Abbott Laboratories

        • 14.5.1 Abbott Laboratories Company Profile

        • 14.5.2 Abbott Laboratories Kidney Cancer Drugs Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 GlaxoSmithKline

        • 14.6.1 GlaxoSmithKline Company Profile

        • 14.6.2 GlaxoSmithKline Kidney Cancer Drugs Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Argos Therapeutics

        • 14.7.1 Argos Therapeutics Company Profile

        • 14.7.2 Argos Therapeutics Kidney Cancer Drugs Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Roche

        • 14.8.1 Roche Company Profile

        • 14.8.2 Roche Kidney Cancer Drugs Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Seattle Genetics

        • 14.9.1 Seattle Genetics Company Profile

        • 14.9.2 Seattle Genetics Kidney Cancer Drugs Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 Onyx Therapeutics

        • 14.10.1 Onyx Therapeutics Company Profile

        • 14.10.2 Onyx Therapeutics Kidney Cancer Drugs Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 AVEO Pharmaceuticals

        • 14.11.1 AVEO Pharmaceuticals Company Profile

        • 14.11.2 AVEO Pharmaceuticals Kidney Cancer Drugs Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Bristol-Myers Squibb

        • 14.12.1 Bristol-Myers Squibb Company Profile

        • 14.12.2 Bristol-Myers Squibb Kidney Cancer Drugs Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Prometheus Laboratories

        • 14.13.1 Prometheus Laboratories Company Profile

        • 14.13.2 Prometheus Laboratories Kidney Cancer Drugs Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Bionomics

        • 14.14.1 Bionomics Company Profile

        • 14.14.2 Bionomics Kidney Cancer Drugs Market Performance

        • 14.14.3 Product&Service Introduction

      • 14.15 ArQule

        • 14.15.1 ArQule Company Profile

        • 14.15.2 ArQule Kidney Cancer Drugs Market Performance

        • 14.15.3 Product&Service Introduction

      • 14.16 Novartis

        • 14.16.1 Novartis Company Profile

        • 14.16.2 Novartis Kidney Cancer Drugs Market Performance

        • 14.16.3 Product&Service Introduction

      • 14.17 Pfizer

        • 14.17.1 Pfizer Company Profile

        • 14.17.2 Pfizer Kidney Cancer Drugs Market Performance

        • 14.17.3 Product&Service Introduction

      • 14.18 Amgen

        • 14.18.1 Amgen Company Profile

        • 14.18.2 Amgen Kidney Cancer Drugs Market Performance

        • 14.18.3 Product&Service Introduction

      • 14.19 Tracon Pharmaceuticals

        • 14.19.1 Tracon Pharmaceuticals Company Profile

        • 14.19.2 Tracon Pharmaceuticals Kidney Cancer Drugs Market Performance

        • 14.19.3 Product&Service Introduction

      • 14.20 Bayer

        • 14.20.1 Bayer Company Profile

        • 14.20.2 Bayer Kidney Cancer Drugs Market Performance

        • 14.20.3 Product&Service Introduction

      • 14.21 Ono Pharmaceutical

        • 14.21.1 Ono Pharmaceutical Company Profile

        • 14.21.2 Ono Pharmaceutical Kidney Cancer Drugs Market Performance

        • 14.21.3 Product&Service Introduction

      • 14.22 immatics biotechnologies

        • 14.22.1 immatics biotechnologies Company Profile

        • 14.22.2 immatics biotechnologies Kidney Cancer Drugs Market Performance

        • 14.22.3 Product&Service Introduction

      • 14.23 Active Biotech

        • 14.23.1 Active Biotech Company Profile

        • 14.23.2 Active Biotech Kidney Cancer Drugs Market Performance

        • 14.23.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Kidney Cancer Drugs Industry Research Conclusions

    • 15.2 Kidney Cancer Drugs Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Kidney Cancer Drugs Industry Market Size (2018-2029)

    • Figure China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of mTOR Inhibitors (2018-2029)

    • Figure China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of Cytokine Immunotherapy (IL-2) (2018-2029)

    • Figure China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of Monoclonal Antibodies (2018-2029)

    • Figure China Kidney Cancer Drugs Production Volume, Production Value and Growth Rate of Angiogenesis Inhibitors (2018-2029)

    • Figure China Kidney Cancer Drugs Sales Volume, Sales Value and Growth Rate of Transitional cell carcinoma (TCC) (2018-2029)

    • Figure China Kidney Cancer Drugs Sales Volume, Sales Value and Growth Rate of Renal cell carcinoma (RCC) (2018-2029)

    • Figure North China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Central China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure South China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure East China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Kidney Cancer Drugs Market Size and Growth Rate from 2018-2029

    • Figure Kidney Cancer Drugs Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Kidney Cancer Drugs Market Share by Type in 2018

    • Figure China Kidney Cancer Drugs Market Share by Type in 2023

    • Figure China Kidney Cancer Drugs Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Kidney Cancer Drugs Production Volume and Growth Rate of mTOR Inhibitors (2018-2023)

    • Figure China Kidney Cancer Drugs Production Volume and Growth Rate of Cytokine Immunotherapy (IL-2) (2018-2023)

    • Figure China Kidney Cancer Drugs Production Volume and Growth Rate of Monoclonal Antibodies (2018-2023)

    • Figure China Kidney Cancer Drugs Production Volume and Growth Rate of Angiogenesis Inhibitors (2018-2023)

    • Figure China Kidney Cancer Drugs Market Share by Application in 2018

    • Figure China Kidney Cancer Drugs Market Share by Application in 2023

    • Figure China Kidney Cancer Drugs Total Market Size and Growth Rate from Consumption End

    • Figure China Kidney Cancer Drugs Market Size and Growth Rate of Transitional cell carcinoma (TCC) (2018-2023)

    • Figure China Kidney Cancer Drugs Market Size and Growth Rate of Renal cell carcinoma (RCC) (2018-2023)

    • Table China Kidney Cancer Drugs Production Volume by Region (2018-2023)

    • Table China Kidney Cancer Drugs Production Volume Share by Region (2018-2023)

    • Figure China Kidney Cancer Drugs Production Volume Share by Region (2018-2023)

    • Table China Kidney Cancer Drugs Production Value by Region (2018-2023)

    • Table China Kidney Cancer Drugs Production Value Share by Region (2018-2023)

    • Figure China Kidney Cancer Drugs Production Value Share by Region (2018-2023)

    • Table China Kidney Cancer Drugs Sales Volume by Region (2018-2023)

    • Table China Kidney Cancer Drugs Sales Volume Share by Region (2018-2023)

    • Figure China Kidney Cancer Drugs Sales Volume Share by Region (2018-2023)

    • Table China Kidney Cancer Drugs Sales Value by Region (2018-2023)

    • Table China Kidney Cancer Drugs Sales Value Share by Region (2018-2023)

    • Figure China Kidney Cancer Drugs Sales Value Share by Region (2018-2023)

    • Table North China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table North China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure North China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table North China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table North China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure North China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Central China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table Central China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Central China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Central China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Central China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Central China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table South China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table South China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure South China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table South China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table South China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure South China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table East China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table East China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure East China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table East China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table East China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure East China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Northeast China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table Northeast China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Northeast China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Northeast China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Northeast China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Southwest China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table Southwest China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Southwest China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Southwest China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Southwest China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Northwest China Kidney Cancer Drugs Production Volume by Type (2018-2023)

    • Table Northwest China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Figure Northwest China Kidney Cancer Drugs Production Volume Share by Type (2018-2023)

    • Table Northwest China Kidney Cancer Drugs Sales Volume by Application (2018-2023)

    • Table Northwest China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Kidney Cancer Drugs Sales Volume Share by Application (2018-2023)

    • Table Exelixis Company Profile

    • Table Exelixis Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Genentech Company Profile

    • Table Genentech Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Taiwan Liposome Company Profile

    • Table Taiwan Liposome Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Wilex Company Profile

    • Table Wilex Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Abbott Laboratories Company Profile

    • Table Abbott Laboratories Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline Company Profile

    • Table GlaxoSmithKline Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Argos Therapeutics Company Profile

    • Table Argos Therapeutics Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Roche Company Profile

    • Table Roche Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Seattle Genetics Company Profile

    • Table Seattle Genetics Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Onyx Therapeutics Company Profile

    • Table Onyx Therapeutics Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table AVEO Pharmaceuticals Company Profile

    • Table AVEO Pharmaceuticals Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Bristol-Myers Squibb Company Profile

    • Table Bristol-Myers Squibb Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Prometheus Laboratories Company Profile

    • Table Prometheus Laboratories Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Bionomics Company Profile

    • Table Bionomics Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table ArQule Company Profile

    • Table ArQule Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Novartis Company Profile

    • Table Novartis Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Pfizer Company Profile

    • Table Pfizer Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Amgen Company Profile

    • Table Amgen Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Tracon Pharmaceuticals Company Profile

    • Table Tracon Pharmaceuticals Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Bayer Company Profile

    • Table Bayer Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Ono Pharmaceutical Company Profile

    • Table Ono Pharmaceutical Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table immatics biotechnologies Company Profile

    • Table immatics biotechnologies Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)

    • Table Active Biotech Company Profile

    • Table Active Biotech Kidney Cancer Drugs Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US